At a glance
- Originator Aphios Corporation
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Japan (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 29 Jun 2009 Paclitaxel prodrug is still in active development